Deuruxolitinib (CTP-543) is a Janus kinase inhibitor selective for JAK1 and JAK2. It is in development to treat alopecia areata.[1] If approved the drug would compete with others with a similar mechanism of action developed by Eli Lilly and Pfizer.[2]
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H10D8N6 |
Molar mass | 314.417 g·mol−1 |
3D model (JSmol) | |
| |
|
Deuruxolitinib is a deuterated derivative of ruxolitinib.
References
edit- ^ King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; Roberts, Janet L.; McMichael, Amy; Colavincenzo, Maria; Hamilton, Colleen; Braman, Virginia; Cassella, James V. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology. 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216. S2CID 247866262.
- ^ Taylor, Nick Paul (2022-05-23). "Chasing Lilly and Pfizer, Concert's JAK inhibitor hits high notes in phase 3 alopecia trial". Fierce Biotech. Retrieved 2023-11-11.